drugset / Trial / NCT01448252

T Cell Vaccination in Patients With Progressive Multiple Sclerosis

NCT01448252 ↗

Phase 1/2 Completed 30 enrolled Hadassah Medical Organization
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double blind phase I-II clinical trial with multiple autologous T cell vaccinations using T cell lines reactive to 9 different myelin peptides of MBP, MOG and PLP, in patients with relapsing progressive Multiple Sclerosis.

Timeline

Start
2002-05
Primary completion
2008-09
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator T cell vaccination Cell therapy — Subcutaneous

Indications